Arovella Therapeutics Limited (ASX:ALA) Suspends Quotation Pending Capital Raise
Arovella Therapeutics Limited (ASX:ALA) suspends ASX trading pending a capital raising announcement.
Arovella Therapeutics Limited (ASX:ALA) suspends ASX trading pending a capital raising announcement.
Keybridge Capital Limited (ASX:KBC) appoints a voluntary administrator amid legal and financial challenges impacting its operations.
CLINUVEL (ASX:CUV) releases preliminary results from the CUV052 study, supporting SCENESSE®’s safety in adolescent EPP patients.
Terramin Australia (ASX:TZN) updates on the legal appeal and operational progress of its Bird in Hand Gold Project, highlighting significant economic benefits for South Australia.
PYC Therapeutics (ASX:PYC) receives regulatory approval to commence human trials for its PKD drug candidate, PYC-003.
Collins Foods (ASX:CKF) clarifies Yum! Brands’ Q4 sales growth, addressing comparability issues and regional inclusions.
Cannindah Resources (ASX:CAE) addresses ASX price query, affirming no undisclosed information impacting recent trading activities.
Godolphin Resources Limited (ASX:GRL) temporarily pauses trading pending further announcements.
Poseidon (ASX:POS) and Horizon Minerals (ASX:HRZ) secure court approval for their merger, effective 10 February 2025.
Nyrada Inc (ASX:NYR) has commenced its Phase Ia clinical trial for NYR-BI03, following HREC approval.